SSSoko Setoguchi

Soko Setoguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soko Setoguchi has a total of 233 co-authors. Here are the top co-authors by number of shared publications:

  • Poonam Gandhi

    Rutgers University Institute for Health, Healthcare Policy, and Aging Research New Brunswick New Jersey USA

    10 shared publications
  • Melanie Rua

    Rutgers University Institute for Health, Healthcare Policy, and Aging Research New Brunswick New Jersey USA

    8 shared publications
  • Benjamin Bates

    Rutgers University Institute for Health, Healthcare Policy, and Aging Research New Brunswick New Jersey USA

    7 shared publications
  • Ashwaghosha Parthasarathi

    Rutgers University Institute for Health, Healthcare Policy, and Aging Research New Brunswick New Jersey USA

    6 shared publications
  • Benjamin Bates

    Department of Medicine, Division of General Internal Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, USA

    6 shared publications
  • David Robinson

    Department of Geography Rutgers University New Brunswick New Jersey USA

    6 shared publications

Latest Publications

  • Open Access

    Climate Change and Medications: Implications for Clinical Practice, Healthcare Sustainability, and Pharmacoepidemiology

    by Soko Setoguchi, Sean Hennessy

    Key Points: The climate‐medication relationship is bidirectional: climate‐amplified exposures such as extreme heat affect medication access, stability, and safety/effectiveness (downstream), while the use and disposal of medications add to healthcare's carbon footprint, thereby contributing to the very warming that intensifies those exposures (upstream). Downstream: Extreme heat, extreme weather, and supply chain disruption are concrete threats to drug stability and access, from mail‐order degradation of insulin and epinephrine to the Hurricane Helene IV‐fluid shortage, and environmental exposures may alter the effects of common medications. Upstream: Therapeutically equivalent options can differ substantially in carbon intensity; eliminating unnecessary prescribing and selecting lower‐carbon therapeutic equivalents are the levers most directly available to prescribers and pharmacists. The evidence base is still immature: current drug‐heat warnings rest largely on mechanistic evidence and case reports, and advancing the field requires linking environmental exposure data to medication outcomes through case‐crossover and time‐series designs, where confounding by indication and polypharmacy represent central challenges. Where lower‐carbon options are already guideline‐concordant, clinicians and pharmacists can act now through prescribing choices, patient education on heat precautions and proper medication storage and disposal, along with healthcare system preparedness. Broader change requires guideline revision, formulary reform, transparent industy data, and collective action through professional societies, including the International Society for Pharmacoepidemiology.

  • Open Access

    A Drug‐Environment Interaction Between PM 2 .5 Concentration and Corticosteroid Use on Cardiovascular and Thromboembolic Events in Older Adults

    by Shu‐Ping Huang, Chien‐Chou Su, Rachel Nethery, Kevin Josey, Benjamin Bates, David Robinson, Poonam Gandhi, Melanie Rua, Ashwaghosha Parthasarathi, Soko Setoguchi, et al.

    Background: Few studies have investigated the interaction between drug‐environment despite the plausibility and concern. We sought to explore the synergistic effects of corticosteroids and PM 2.5 on cardiovascular and thromboembolic events in high‐risk older adults in Taiwan. Objectives: To assess the synergistic effect of corticosteroid use and PM 2.5 exposure on cardiovascular and thromboembolic events and all cause mortality among elderly individuals in Taiwan. Methods: We conducted a retrospective cohort study using the Taiwan National Health Insurance database from 2009 to 2019. We included patients aged 65 years or older and at high risk for cardiovascular and thromboembolic events. Exposures included corticosteroid therapy and seasonal mean PM 2.5 . Primary outcomes included myocardial infarction or acute coronary syndrome, ischemic stroke or transient ischemic attack, heart failure, venous thromboembolism, atrial fibrillation, and all‐cause mortality. We then fitted history‐adjusted marginal structural Cox proportional hazard models to investigate both the independent and synergistic effects of PM 2.5 and corticosteroid use on the CTE outcomes. We measured whether there was a sufficient cause interaction between PM 2.5 and corticosteroids using estimates of relative excess risk due to interaction (RERI). Results: The cohort included 373 402 participants, with average age at index date 73.6 ± 7.2 years; 57.7% of cohort members were female. During the study period, 1 614 331 (43.2%) participants had at least one corticosteroid prescription. The average PM 2.5 concentration was 28.3 ± 17.4 μg/m 3 . Increasing PM 2.5 from 15 to 20 μg/m 3 resulted in significantly increased excess risk due to interaction (RERI [95% CI]) for all‐cause mortality (3.1% [0.27%, 5.9%]). Conclusions: A synergistic effect between seasonal PM 2.5 exposure and corticosteroid use was found on all‐cause mortality in elderly patients at high risk for cardiovascular and thromboembolic events.

  • Open Access

    Accuracy of New Hypertensive Crisis Diagnoses Using International Classification of Disease (ICD)‐10: A Validation Study in a National Medicare Sample

    by Aayush Visaria, Ashwaghosha Parthasarathi, Poonam Gandhi, Benjamin Bates, Melanie Rua, Tobias Gerhard, Samanvaya Sharma, Matthew Pelton, Conan Chen, Seung Jae Moon, et al.

    The incidence of hypertensive (HTN) crises in older adults has more than doubled over the past two decades. ICD‐10 introduced codes for HTN urgency and emergency, but their validity has not been evaluated. We analyzed a 20% national sample of fee‐for‐service Medicare beneficiaries aged ≥66 years (2016–2019). Medical records were reviewed for 220 randomly sampled emergency department visits or hospitalizations with a primary ICD‐10 HTN crisis code (100 HTN urgency [I16.0], 100 HTN emergency [I16.1] and 20 unspecified [I16.9]). Physicians abstracted and adjudicated cases. Two gold standards (GS) were used: (1) treating physician diagnosis and (2) adjudicated diagnosis based on BP (SBP ≥180 mmHg or DBP ≥110 mmHg), with or without end‐organ damage. PPVs and 95% confidence intervals were estimated. Among 220 charts sampled from 53,100 HTN crisis cases (mean age 73 years; 33% male; 66% White), PPV for HTN emergency (I16.1) was 91% (95% CI, 85%–96%) using the treating physician GS and 78% (95% CI, 71%–86%) using the adjudicated GS. PPV for HTN urgency (I16.0) was 97% (95% CI, 93%–99%) and 81% (95% CI, 72%–88%), respectively. Overall PPV for any HTN crisis (I16.X) using the adjudicated GS was 95% (95% CI, 91%–97%). Including unspecified codes reduced PPV to 86% (95% CI, 79%–92%) and 78% (95% CI, 71–86%). ICD‐10 HTN crisis codes demonstrate high PPV, supporting their use in epidemiologic and health services research.


  • Open Access

    Excess risk of heat-related hospitalization associated with temperature and PM2.5 among older adults

    by Lauren Mock, Rachel C. Nethery, Poonam Gandhi, Ashwaghosha Parthasarathi, Melanie Rua, David Robinson, Soko Setoguchi, Kevin Josey

    Background: With rising temperatures and an aging population, understanding how to prevent heat-related illness among older adults will be increasingly crucial. Despite biological plausibility, no study to date has investigated how exposure to fine particulate matter air pollution (PM 2.5 ) may contribute to the risk of hospitalization with a diagnosis code indicating heat-related illness, referred to as heat-related hospitalization. This study aims to fill this gap by investigating the independent and combined effects of temperature and PM 2.5 exposures on heat-related hospitalization risk. Methods: We identified Medicare fee-for-service beneficiaries in the contiguous United States who experienced a heat-related hospitalization between 2008 and 2016. Using a case-crossover design and fitting Bayesian conditional logistic regression models, we characterized the associations of temperature and PM 2.5 exposures with heat-related hospitalization. We then estimated the relative excess risk due to interaction to quantify the additive-scale interaction of simultaneous exposure to heat and PM 2.5 . Results: We observed 112,969 heat-related hospitalizations among 29,345,820 Medicare beneficiaries in the study sample. Fixing PM 2.5 at the case day median, the odds ratio for increasing temperature from its case day median to the 95th percentile was 1.05 (95% CI: 1.03, 1.06). Fixing temperature at the case day median, the odds ratio for increasing PM 2.5 from its median to the 95th percentile was 1.01 (95% CI: 0.99, 1.04). The risk due to interaction for simultaneous median-to-95th percentile increases in temperature and PM 2.5 was 0.03 (95% CI: 0.01, 0.06). Conclusions: Our study is the first to observe synergism between temperature and PM 2.5 exposures associated with the risk of heat-related hospitalization. These findings highlight the importance of considering air pollution in effective public health and clinical interventions to prevent heat-related illness.


  • Open Access

    Exposure–Response to High PM 2.5 Levels for Cardiovascular Events in High‐Risk Older Adults in Taiwan

    by Shu‐Ping Huang, Chien‐Chou Su, Chuan‐Yao Lin, Rachel Nethery, Kevin Josey, Benjamin Bates, David Robinson, Poonam Gandhi, Melanie Rua, Ashwaghosha Parthasarathi, et al.

    Background: Limited studies using individual‐level health outcome data exist from countries with a wider range of particulate matter with a diameter of 15 μg/m 3 PM 2.5 concentrations. Taiwan reduced PM 2.5 over time with its policies, which provide opportunities to illustrate the dose–response curves and how reductions of PM 2.5 over time correlated with cardiovascular events incidence in a nationwide sample. Methods: Using data from the 2009 to 2019 Taiwan National Health Insurance Database linked to nationwide PM 2.5 data, we examined the magnitude of the exposure–response curve between seasonal average PM 2.5 level and cardiovascular events‐related hospitalizations among older adults at high risk for cardiovascular events. We used history‐adjusted marginal structural models including potential confounding by individual demographic factors, baseline comorbidities, and health service measures. Results: We included 373 402 older adults with high‐risk conditions in Taiwan. Using the PM 2.5 concentration 23.5 μg/m 3 ) were associated with hazard ratio of 1.13 (95% CI, 1.09–1.18) and 1.19 (95% CI, 1.14–1.24), 1.07 (95% CI, 1.03–1.11) and 1.14 (95% CI, 1.10–1.18), 1.22 (95% CI, 1.08–1.38) and 1.31 (95% CI, 1.16–1.48), 1.04 (95% CI, 0.98–1.10) and 1.10 (95% CI, 1.04–1.16), respectively, for heart failure, ischemic stroke/transient ischemic attack, deep vein thrombosis, and myocardial infarction/acute coronary syndrome. Conclusions: Further lowering PM 2.5 levels beyond current regulatory standards (15 μg/m 3 ) may effectively reduce the incidence of heart failure, deep vein thrombosis, and ischemic stroke/transient ischemic attack, and can lead to tangible health benefits in the high‐risk older population.


  • Open Access

    Supplemental Table 1 from Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?

    by Saber A. Amin, Lindsay J. Collin, Soko Setoguchi, Jaya M. Satagopan, Alexandre Buckley de Meritens, Elisa V. Bandera

    Supplemental Table 1 shows Hazard ratios and 95% confidence intervals for racial and ethnic disparities in all-cause mortality among 37,566 ovarian cancer patients diagnosed with stage III/IV disease in the National Cancer Database (2004–2017) stratified by treatment sequence

  • Open Access

    Supplemental Table 2 from Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?

    by Saber A. Amin, Lindsay J. Collin, Soko Setoguchi, Jaya M. Satagopan, Alexandre Buckley de Meritens, Elisa V. Bandera

    Supplemental Table 2 shows Hazard ratios and 95% confidence intervals for racial and ethnic disparities in all-cause mortality of ovarian cancer patients diagnosed with stage III/IV disease in the National Cancer Database (2004–2017) using the cut-off points of 30, 60, and 90 days after surgery as the start of time for follow-up in landmark analysis

  • Open Access

    Data from Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?

    by Saber A. Amin, Lindsay J. Collin, Soko Setoguchi, Jaya M. Satagopan, Alexandre Buckley de Meritens, Elisa V. Bandera

    Background:We investigated racial and ethnic disparities in treatment sequence [i.e., neoadjuvant chemotherapy (NACT) plus interval debulking surgery (IDS) versus primary debulking surgery (PDS) plus adjuvant chemotherapy] among patients with ovarian cancer and its contribution to disparities in mortality.Methods:Study included 37,566 women ages ≥18 years, diagnosed with stage III/IV ovarian cancer from the National Cancer Database (2004–2017). Logistic regression was used to compute ORs and 95% confidence intervals (CI) for racial and ethnic disparities in treatment sequence. Cox proportional hazards regression was used to estimate HRs and 95% CI for racial and ethnic disparities in all-cause mortality.Results:Non-Hispanic Black (NHB) and Asian women were more likely to receive NACT plus IDS relative to PDS plus adjuvant chemotherapy than non-Hispanic White (NHW) women (OR: 1.12; 95% CI: 1.02–1.22 and OR: 1.12; 95% CI: 0.99–1.28, respectively). Compared with NHW women, NHB women had increased hazard of all-cause mortality (HR: 1.14; 95% CI: 1.09–1.20), whereas Asian and Hispanic women had a lower hazard of all-cause mortality (HR: 0.81; 95% CI: 0.74–0.88 and HR: 0.83; 95% CI: 0.77–0.88, respectively), which did not change after accounting for treatment sequence.Conclusions:NHB women were more likely to receive NACT plus IDS and experience a higher all-cause mortality rates than NHW women.Impact:Differences in treatment sequence did not explain racial disparities in all-cause mortality. Further evaluation of racial and ethnic differences in treatment and survival in a cohort of patients with detailed treatment information is warranted.

  • Open Access

    The Association of Long COVID and CKD

    by A. Jerrod Anzalone, Spencer Krichevsky, Yun Jae Yoo, Kenneth J. Wilkins, Fadhl Alakwaa, Feifan Liu, Ankit Sakhuja, Joel H. Saltz, Yun Han, Richard L. Zhu, et al.

    Key Points: Baseline CKD, even mild, is associated with a higher risk of long coronavirus disease (COVID) in patients with acute severe acute respiratory syndrome coronavirus infection. Among those without CKD at baseline, Long COVID is associated with a higher risk of developing new CKD and faster kidney function decline. Associations between Long COVID and CKD/kidney function decline persist after matching, adjustment, and accounting for the competing risk of death. Background: Among patients with acute coronavirus disease-19 (COVID-19), the association of CKD and Long COVID has not been reported in large multicenter cohorts. Methods: This study used data from 59 health care systems across the United States, in the National Clinical Cohort Collaborative COVID enclave, to analyze the relationship between CKD and Long COVID among adults diagnosed with acute COVID-19 between October 2021 and September 2023. We conducted two main analyses. First analysis : we tested if baseline CKD (eGFR 2 or diagnostic code) or baseline ESKD are risk factors for Long COVID (identified using ICD-10-CM code U09.9). We secondarily assessed associations between baseline mild CKD (Stage 3a, eGFR 45–59 ml/min per 1.73 m 2 ) and Long COVID. Second Analysis : among patients without baseline CKD/ESKD, we examined if incident CKD/ESKD and eGFR decline (≥20% in 1 year) were associated with Long COVID. We used propensity score matching for demographics and data contributing site, with models adjusted for risk factors and competing risk of death. All outcomes were evaluated within a 365-day follow-up period from the onset of acute COVID-19. Results: First analysis : From an unmatched cohort of 2,385,20 patients with acute COVID-19, those with baseline CKD/ESKD had a higher risk of Long COVID (adjusted subdistribution hazard ratio [sHR], 1.13; 95% confidence interval [CI], 1.09 to 1.18) after matching. A similar risk was noted even among those with mild CKD (sHR, 1.15; 95% CI, 1.05 to 1.25). Second Analysis: Among patients with acute COVID-19 and without baseline CKD/ESKD, Long COVID was associated with incident CKD/ESKD (sHR, 1.65; 95% CI, 1.51 to 1.81) and 20% or greater eGFR decline (sHR, 1.21; 95% CI 1.04 to 1.40) within 1 year. Conclusions: CKD, even mild, was associated with an higher risk of Long COVID. Among those without baseline CKD, Long COVID was associated with incident CKD and eGFR decline.